Suppr超能文献

澳大利亚腹膜透析患者的肠球菌性腹膜炎:116 例患者的预测因素、治疗和结局。

Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases.

机构信息

Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.

出版信息

Nephrol Dial Transplant. 2010 Apr;25(4):1272-8. doi: 10.1093/ndt/gfp641. Epub 2009 Nov 30.

Abstract

UNLABELLED

Background. Enterococcal peritonitis is a serious complication of peritoneal dialysis (PD), although reports of this condition in the literature are exceedingly limited. Methods. The frequency, predictors, treatment and clinical outcomes of enterococcal peritonitis were investigated in all 4675 patients receiving PD in Australia between 1 October 2003 and 31 December 2006. Results. One hundred and sixteen episodes of enterococcal peritonitis occurred in 103 individuals. Enterococcal peritonitis tended to be associated with older age, Maori and Pacific Islander racial origin, renovascular disease and coronary artery disease. Polymicrobial peritonitis, defined as recovery of two or more organisms from dialysate effluent, was significantly more common when an Enterococcus species was isolated than when it was not (45% vs 5%, respectively, P < 0.001, odds ratio 13.4, 95% CI 9.45-19.0). Although international guidelines recommend intraperitoneal ampicillin therapy, only 8% of patients with pure enterococcal peritonitis were treated with this agent, whilst the majority (78%) received vancomycin monotherapy. Overall, 59 (51%) patients with enterococcal peritonitis were successfully treated with antibiotics without experiencing relapse, catheter removal or death. The sole independent predictor of adverse clinical outcomes was recovery of additional (non-Enterococcus) organisms. Polymicrobial enterococcal peritonitis was associated with very high rates of hospitalization (83%), catheter removal (52%), permanent haemodialysis transfer (50%) and death (5.8%). In contrast, clinical outcomes were broadly comparable for pure enterococcal and non-enterococcal peritonitis (hospitalization 75% vs 69%, respectively; catheter removal 25% vs 21%; permanent haemodialysis transfer 17% vs 17%; death 1.6% vs 2.2%) although worse than non-enterococcal Gram-positive peritonitis (63%, 12%, 3% and 0.6%, respectively). Removal of the PD catheter within 1 week of enterococcal peritonitis onset was associated with a lower probability of permanent haemodialysis transfer than later removal (74% vs 100%, P = 0.03).

CONCLUSIONS

Enterococcal peritonitis is associated with an increased risk of catheter removal, permanent haemodialysis transfer and death, particularly when other organisms are isolated in the same episode.

摘要

背景

肠球菌性腹膜炎是腹膜透析(PD)的严重并发症,尽管文献中对此类疾病的报道极为有限。

方法

研究人员对 2003 年 10 月 1 日至 2006 年 12 月 31 日期间在澳大利亚接受 PD 治疗的 4675 例患者的肠球菌性腹膜炎的发生频率、预测因素、治疗方法和临床结局进行了调查。

结果

103 名患者发生了 116 例肠球菌性腹膜炎。肠球菌性腹膜炎往往与年龄较大、毛利人和太平洋岛民种族、肾血管疾病和冠状动脉疾病有关。当从透析液中分离出两种或两种以上的病原体时,被定义为混合性腹膜炎的情况明显更为常见(分别为 45%和 5%,P<0.001,优势比 13.4,95%CI 9.45-19.0)。尽管国际指南建议使用腹腔内氨苄西林治疗,但只有 8%的单纯肠球菌性腹膜炎患者接受了这种治疗,而大多数(78%)患者接受了万古霉素单药治疗。总的来说,59 例(51%)肠球菌性腹膜炎患者在未发生复发、导管拔除或死亡的情况下成功接受了抗生素治疗。唯一的独立不良临床结局预测因素是分离出其他(非肠球菌)病原体。混合性肠球菌性腹膜炎与高住院率(83%)、导管拔除(52%)、永久性血液透析转归(50%)和死亡率(5.8%)密切相关。相比之下,单纯性肠球菌性和非肠球菌性腹膜炎的临床结局大致相似(分别为 75%和 69%的住院率,25%和 21%的导管拔除率,17%和 17%的永久性血液透析转归率,1.6%和 2.2%的死亡率),尽管不如非肠球菌性革兰阳性腹膜炎(分别为 63%、12%、3%和 0.6%)。与肠球菌性腹膜炎发病后 1 周内拔管相比,发病后 1 周后拔管与永久性血液透析转归率较低相关(分别为 74%和 100%,P=0.03)。

结论

肠球菌性腹膜炎与导管拔除、永久性血液透析转归和死亡风险增加有关,尤其是当同一病例中分离出其他病原体时。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验